BalonRMorrealeMK. The precipitous decline of academic medicine in the United States. Ann Clin Psychiatry.2020; 32: 225–227.
2.
LaughrenT P. A growing crisis in schizophrenia drug development: failing signal detection at North American and other clinical trial sites. J Clin Psychiatry.2020; 81: 19com13110. doi:10.4088/JCP.19com13110
3.
MarkowitzJCFriedmanRA. NIM H's straight and neural path: the road to killing clinical psychiatric research. Psychiatr Serv.2020; 71: 1096–1097.
4.
TorreyEFKnableMBRushAJUsing the NIH research, condition and disease categorization database for research advocacy: schizophrenia research at NIMH as an example. PLoS One.2020; 15: e0241062. doi:10.1371/journal.pone.0241062
5.
Institute of Medicine; Committee on the NIH Research Priority-Setting Process.Preface. Scientific opportunities and public needs: improving priority setting and public input at the National Institutes of Health. National Academies Press; 1998.
6.
TorreyEFYolkenRHLambRH. NIMH drug trials for schizophrenia. J Clin Psychiatry.2019; 80: 18com12597. doi:10.4088/JCP.18com12597
7.
GordonJA. NIMH supports evidence-based treatments for schizophrenia: a response to Torrey et al. J Clin Psychiatry.2019; 80: 18com12597a. doi:10.4088/JCP.18com12597a
8.
KupferDJFrankEPerelJMFive-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry.1992; 49: 769–773.
9.
KleinD F. The loss of serendipity in psycho-pharmacology. JAMA.2008; 299: 1063–1065.
